Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"Foresite Capital","pharmaFlowCategory":"D","amount":"$81.0 million","upfrontCash":"Undisclosed","newsHeadline":"Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$1,045.0 million","upfrontCash":"$45.0 million","newsHeadline":"Remix Therapeutics Enters Collaboration with Janssen to Advance Small Molecule Therapeutics Using REMaster Drug Discovery Platform to Modulate RNA Processing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,042.0 million","upfrontCash":"$30.0 million","newsHeadline":"Remix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by Remix Therapeutics

    Menu

    Remix Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Remix Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Remix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing

              Details:

              Under the collaboration, Roche will advance discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform and will have exclusive rights to specific targets.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

              Deal Size: $1,042.0 million Upfront Cash: $30.0 million

              Deal Type: Collaboration January 03, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Remix Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Remix Therapeutics Enters Collaboration with Janssen to Advance Small Molecule Therapeutics Using REMaster Drug Discovery Platform to Modulate RNA Processing

              Details:

              Under the terms of the agreement, Remix will receive preclinical, clinical, commercial, and sales milestone payments and tiered royalties for products. In exchange, Janssen will have exclusive rights to three specific targets with applications in immunology and oncology.

              Lead Product(s): Undisclosed

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

              Deal Size: $1,045.0 million Upfront Cash: $45.0 million

              Deal Type: Collaboration February 17, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Remix Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing

              Details:

              The funds will support development of the company’s REMaster technology platform and advancement of a pipeline of RNA processing targeted therapeutics.

              Lead Product(s): RNA processing targeted therapeutics

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Foresite Capital

              Deal Size: $81.0 million Upfront Cash: Undisclosed

              Deal Type: Financing December 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY